Plasma proteomic profiling for detecting and differentiating in situ and invasive carcinomas of the uterine cervix

Y. W. Lin, H. C. Lai, C. Y. Lin, J. Y. Chiou, H. A. Shui, C. C. Chang, M. H. Yu, T. Y. Chu

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The objective of this study was to identify multiple plasma protein markers that might be characteristic of in situ and invasive cervical cancers. Plasma samples obtained from patients with in situ cervical cancer (carcinoma in situ [CIS], n = 32), from patients with early invasive cervical cancer without lymph node metastasis (squamous cell carcinoma [SCC], n = 60), and from age-matched disease-free controls (n = 37) were analyzed by cation-exchange protein chips and surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. A classification tree defined by six protein peaks could discriminate 84 of the 92 cancers (CIS and SCC) and 36 of the 37 controls, with 91% sensitivity and 97% specificity. In comparing the CIS and SCC samples, two protein peaks with Mr values of 6586.41 and 3805.68 were able to classify 55 of the 60 SCC and 31 of the 32 CIS samples, with 92% sensitivity and 97% specificity. This study demonstrates for the first time the feasibility of differentiating in situ and invasive cervical cancers through plasma protein profiling. Identification of the proteins different in invasive and in situ cancer may be of great value in the understanding of cervical cancer invasion and in the development of novel therapeutic intervention.

Original languageEnglish
Pages (from-to)1216-1224
Number of pages9
JournalInternational Journal of Gynecological Cancer
Volume16
Issue number3
DOIs
Publication statusPublished - May 2006
Externally publishedYes

Fingerprint

Carcinoma in Situ
Cervix Uteri
Uterine Cervical Neoplasms
Proteomics
Squamous Cell Carcinoma
Blood Proteins
Antiporters
Sensitivity and Specificity
Protein Array Analysis
Proteins
Mass Spectrometry
Neoplasms
Lasers
Lymph Nodes
Neoplasm Metastasis

Keywords

  • Cervical cancer
  • Protein chip
  • SELDI-TOF mass spectrometry

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research

Cite this

Plasma proteomic profiling for detecting and differentiating in situ and invasive carcinomas of the uterine cervix. / Lin, Y. W.; Lai, H. C.; Lin, C. Y.; Chiou, J. Y.; Shui, H. A.; Chang, C. C.; Yu, M. H.; Chu, T. Y.

In: International Journal of Gynecological Cancer, Vol. 16, No. 3, 05.2006, p. 1216-1224.

Research output: Contribution to journalArticle

Lin, Y. W. ; Lai, H. C. ; Lin, C. Y. ; Chiou, J. Y. ; Shui, H. A. ; Chang, C. C. ; Yu, M. H. ; Chu, T. Y. / Plasma proteomic profiling for detecting and differentiating in situ and invasive carcinomas of the uterine cervix. In: International Journal of Gynecological Cancer. 2006 ; Vol. 16, No. 3. pp. 1216-1224.
@article{46db2b71480b43578576b3dc84a4a396,
title = "Plasma proteomic profiling for detecting and differentiating in situ and invasive carcinomas of the uterine cervix",
abstract = "The objective of this study was to identify multiple plasma protein markers that might be characteristic of in situ and invasive cervical cancers. Plasma samples obtained from patients with in situ cervical cancer (carcinoma in situ [CIS], n = 32), from patients with early invasive cervical cancer without lymph node metastasis (squamous cell carcinoma [SCC], n = 60), and from age-matched disease-free controls (n = 37) were analyzed by cation-exchange protein chips and surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. A classification tree defined by six protein peaks could discriminate 84 of the 92 cancers (CIS and SCC) and 36 of the 37 controls, with 91{\%} sensitivity and 97{\%} specificity. In comparing the CIS and SCC samples, two protein peaks with Mr values of 6586.41 and 3805.68 were able to classify 55 of the 60 SCC and 31 of the 32 CIS samples, with 92{\%} sensitivity and 97{\%} specificity. This study demonstrates for the first time the feasibility of differentiating in situ and invasive cervical cancers through plasma protein profiling. Identification of the proteins different in invasive and in situ cancer may be of great value in the understanding of cervical cancer invasion and in the development of novel therapeutic intervention.",
keywords = "Cervical cancer, Protein chip, SELDI-TOF mass spectrometry",
author = "Lin, {Y. W.} and Lai, {H. C.} and Lin, {C. Y.} and Chiou, {J. Y.} and Shui, {H. A.} and Chang, {C. C.} and Yu, {M. H.} and Chu, {T. Y.}",
year = "2006",
month = "5",
doi = "10.1111/j.1525-1438.2006.00583.x",
language = "English",
volume = "16",
pages = "1216--1224",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Plasma proteomic profiling for detecting and differentiating in situ and invasive carcinomas of the uterine cervix

AU - Lin, Y. W.

AU - Lai, H. C.

AU - Lin, C. Y.

AU - Chiou, J. Y.

AU - Shui, H. A.

AU - Chang, C. C.

AU - Yu, M. H.

AU - Chu, T. Y.

PY - 2006/5

Y1 - 2006/5

N2 - The objective of this study was to identify multiple plasma protein markers that might be characteristic of in situ and invasive cervical cancers. Plasma samples obtained from patients with in situ cervical cancer (carcinoma in situ [CIS], n = 32), from patients with early invasive cervical cancer without lymph node metastasis (squamous cell carcinoma [SCC], n = 60), and from age-matched disease-free controls (n = 37) were analyzed by cation-exchange protein chips and surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. A classification tree defined by six protein peaks could discriminate 84 of the 92 cancers (CIS and SCC) and 36 of the 37 controls, with 91% sensitivity and 97% specificity. In comparing the CIS and SCC samples, two protein peaks with Mr values of 6586.41 and 3805.68 were able to classify 55 of the 60 SCC and 31 of the 32 CIS samples, with 92% sensitivity and 97% specificity. This study demonstrates for the first time the feasibility of differentiating in situ and invasive cervical cancers through plasma protein profiling. Identification of the proteins different in invasive and in situ cancer may be of great value in the understanding of cervical cancer invasion and in the development of novel therapeutic intervention.

AB - The objective of this study was to identify multiple plasma protein markers that might be characteristic of in situ and invasive cervical cancers. Plasma samples obtained from patients with in situ cervical cancer (carcinoma in situ [CIS], n = 32), from patients with early invasive cervical cancer without lymph node metastasis (squamous cell carcinoma [SCC], n = 60), and from age-matched disease-free controls (n = 37) were analyzed by cation-exchange protein chips and surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. A classification tree defined by six protein peaks could discriminate 84 of the 92 cancers (CIS and SCC) and 36 of the 37 controls, with 91% sensitivity and 97% specificity. In comparing the CIS and SCC samples, two protein peaks with Mr values of 6586.41 and 3805.68 were able to classify 55 of the 60 SCC and 31 of the 32 CIS samples, with 92% sensitivity and 97% specificity. This study demonstrates for the first time the feasibility of differentiating in situ and invasive cervical cancers through plasma protein profiling. Identification of the proteins different in invasive and in situ cancer may be of great value in the understanding of cervical cancer invasion and in the development of novel therapeutic intervention.

KW - Cervical cancer

KW - Protein chip

KW - SELDI-TOF mass spectrometry

UR - http://www.scopus.com/inward/record.url?scp=33745086206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745086206&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2006.00583.x

DO - 10.1111/j.1525-1438.2006.00583.x

M3 - Article

VL - 16

SP - 1216

EP - 1224

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 3

ER -